Hmn-372 __top__ -

: In chemistry or pharmacology, such a code might refer to a specific compound being researched or developed. Without more context, it's hard to say if HMN-372 is a drug candidate, a chemical intermediate, or another type of compound.

The compound is often discussed alongside other "triple-threat" or dual-blocking therapies, such as Ivonescimab, which target multiple pathways to overcome the drug resistance commonly seen in advanced cancers. Key Mechanisms and Applications HMN-372